Dr Lindsay Strowd, from the Wake Forest School of Medicine, Winston-Salem, North Carolina, reports on key findings on atopic dermatitis (AD) presented at the American Academy of Dermatology 2022 Annual Meeting.
First, she discusses updates to the clinical guidelines that address comorbidities linked with AD. On this theme, Dr Strowd presents a study that found associations between AD and delinquent behavior in children and another study linking long-term sleep issues in adults with severe AD.
Next, Dr Strowd analyzes two studies that looked at patients treated with dupilumab. The first, a retrospective cohort study across 12 locations in Canada, supports recommendations that individuals with AD should not discontinue therapy because of fear of contracting COVID-19. The second, a single-arm, observational study, assessed whether dupilumab in patients with moderate to severe AD decreased concomitant therapies.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Atopic Dermatitis Highlights From AAD 2022 - Medscape - Apr 18, 2022.
Comments